Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CDC25B | P30305 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | CA3 | P07451 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1557301 | 0.78 | ALDH1A1 (0.50) | ALDH1A1HSD17B10CYP3A4TSHRHPGD | |
| SCHEMBL87812 | 0.78 | KDM4E (0.52) | ALDH1A1HSD17B10CYP3A4TSHRHPGD | |
| SCHEMBL31682387 | 0.78 | ALDH1A1 (0.50) | ALDH1A1HSD17B10CYP3A4TSHRHPGD | |
| SCHEMBL6768843 | 0.78 | ALDH1A1 (0.50) | ALDH1A1HSD17B10CYP3A4TSHRHPGD | |
| SCHEMBL9613866 | 0.78 | L3MBTL1 (0.35) | ALDH1A1HSD17B10HPGDKDM4ERECQL | |
| SCHEMBL49213 | 0.74 | HSD17B10 (0.74) | ALDH1A1HSD17B10CYP3A4TSHRHPGD | |
| SCHEMBL7915675 | 0.74 | ALDH1A1 (0.60) | ALDH1A1HSD17B10CYP3A4TSHRHPGD | |
| SCHEMBL2099990 | 0.72 | ALDH1A1 (0.48) | ALDH1A1HSD17B10CYP3A4TSHRHPGD | |
| SCHEMBL1921580 | 0.72 | HSD17B10 (0.71) | ALDH1A1HSD17B10CYP3A4TSHRHPGD | |
| SCHEMBL8500339 | 0.72 | HSD17B10 (0.71) | ALDH1A1HSD17B10CYP3A4TSHRHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0520336-A2 | Aldehyde derivatives and their use as calpain inhibitors | FUJIREBIO Inc. (JP) | 1992-12-30 | — | — | EP | claimed |
| US-8163767-B2 | Heterocyclic Janus Kinase 3 inhibitors | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| CN-102127078-A | Heterocyclic janus kinase 3 inhibitors | ASTELLAS PHARMA INC | 2011-07-20 | — | — | CN | disclosed |
| EP-2251341-A1 | Heterocyclic Janus kinase 3 inhibitors | Astellas Pharma Inc. (JP) | 2010-11-17 | — | — | EP | disclosed |
| US-7786079-B2 | Substituted nonadepsipeptides | AICURIS GMBH & CO. KG. (DE) | 2010-08-31 | — | — | US | disclosed |
| EP-1809653-B1 | SUBSTITUTED NONADEPSIPEPTIDES | AICURIS GMBH & CO KG (DE) | 2010-01-20 | — | — | EP | disclosed |
| US-20090264399-A1 | HETEROCYCLIC JANUS KINASE 3 INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2009-10-22 | — | — | US | disclosed |
| US-7465731-B2 | HDAC inhibitor | ASTELLAS PHARMA INC. (JP) | 2008-12-16 | — | — | US | disclosed |
| CN-101223168-A | Heterocyclic JANUS kinase 3 inhibitors | ASTELLAS PHARMA INC (JP) | 2008-07-16 | — | — | CN | disclosed |
| US-20080058251-A1 | Substituted nonadepsipeptides | BAYER HEALTHCARE AG (DE) | 2008-03-06 | — | — | US | disclosed |
| US-5162522-A | Method for producing cephem compounds | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-11-10 | — | — | US | disclosed |
| US-5120738-A | Cardiovascular disorders | FUJIREBIO INC. (JP) | 1992-06-09 | — | — | US | disclosed |
| US-5043372-A | Light stabilizers for polyolefins; reacting hydrazine with bis(half ester-half amide) | ATOCHEM NORTH AMERICA, INC. (US) | 1991-08-27 | — | — | US | disclosed |
| EP-0434079-A1 | N,N'-hydrocarbylenebis(N-hals-substituted amic acid hydrazides) and their derivatives | ELF ATOCHEM NORTH AMERICA, INC. (US) | 1991-06-26 | — | — | EP | disclosed |
| EP-0421441-A2 | Pantothenic acid derivatives | FUJIREBIO INC. (JP) | 1991-04-10 | — | — | EP | disclosed |
| US-4933355-A | ALDOSE REDUCTASE INHIBITORS | SANKYO COMPANY LIMITED (JP) | 1990-06-12 | — | — | US | disclosed |
| US-4929639-A | TREATMENT OF ASTHMA, DISEASES CAUSED BY THROMBOXANE A2 | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1990-05-29 | — | — | US | disclosed |
| EP-0354538-A2 | Method for producing cephem compounds | Takeda Chemical Industries, Ltd. (JP) | 1990-02-14 | — | — | EP | disclosed |
| EP-0346511-A1 | Oxygen-containing hererocyclic compound, processes for their preparation and pharmaceutical compositions comprising them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-12-20 | — | — | EP | disclosed |
| EP-0337819-A1 | Thiazole derivatives, their preparation and their use in the treatment of diabetes complications | Sankyo Company Limited (JP) | 1989-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058251-A1 | Substituted nonadepsipeptides | VIP, DNPEP, LNPEP | ALDH1A1 4758/4885HSD17B10 3473/4885CYP3A4 4433/4885 |
| US-20090264399-A1 | HETEROCYCLIC JANUS KINASE 3 INHIBITORS | JAK3, JAK2, JAK1 | ALDH1A1 3392/4885HSD17B10 3943/4885CYP3A4 1889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.